全文获取类型
收费全文 | 3318104篇 |
免费 | 257130篇 |
国内免费 | 6473篇 |
专业分类
耳鼻咽喉 | 49883篇 |
儿科学 | 103593篇 |
妇产科学 | 91613篇 |
基础医学 | 463640篇 |
口腔科学 | 99154篇 |
临床医学 | 296240篇 |
内科学 | 641379篇 |
皮肤病学 | 71547篇 |
神经病学 | 275724篇 |
特种医学 | 133616篇 |
外国民族医学 | 1263篇 |
外科学 | 508243篇 |
综合类 | 78849篇 |
现状与发展 | 7篇 |
一般理论 | 1325篇 |
预防医学 | 255299篇 |
眼科学 | 80925篇 |
药学 | 249696篇 |
6篇 | |
中国医学 | 6469篇 |
肿瘤学 | 173236篇 |
出版年
2018年 | 33488篇 |
2016年 | 29260篇 |
2015年 | 32990篇 |
2014年 | 46512篇 |
2013年 | 70773篇 |
2012年 | 95107篇 |
2011年 | 99894篇 |
2010年 | 58929篇 |
2009年 | 56372篇 |
2008年 | 95446篇 |
2007年 | 102430篇 |
2006年 | 103329篇 |
2005年 | 101334篇 |
2004年 | 97483篇 |
2003年 | 94420篇 |
2002年 | 93104篇 |
2001年 | 151914篇 |
2000年 | 156797篇 |
1999年 | 132506篇 |
1998年 | 35867篇 |
1997年 | 32299篇 |
1996年 | 31446篇 |
1995年 | 32219篇 |
1994年 | 30212篇 |
1993年 | 28080篇 |
1992年 | 105665篇 |
1991年 | 102075篇 |
1990年 | 99090篇 |
1989年 | 95841篇 |
1988年 | 88992篇 |
1987年 | 87737篇 |
1986年 | 83528篇 |
1985年 | 79836篇 |
1984年 | 60280篇 |
1983年 | 51251篇 |
1982年 | 31149篇 |
1981年 | 27882篇 |
1979年 | 57224篇 |
1978年 | 40469篇 |
1977年 | 34550篇 |
1976年 | 31951篇 |
1975年 | 34800篇 |
1974年 | 42271篇 |
1973年 | 40527篇 |
1972年 | 38419篇 |
1971年 | 35788篇 |
1970年 | 33783篇 |
1969年 | 31665篇 |
1968年 | 29218篇 |
1967年 | 26217篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
Thomas Fuchs-Buder Sorin J. Brull Malin Jonsson Fagerlund J. Ross Renew Guy Cammu Glenn S. Murphy Michiel Warlé Matias Vested Béla Fülesdi Reka Nemes Malachy O. Columb Daniela Damian Peter J. Davis Hajime Iwasaki Lars I. Eriksson 《Acta anaesthesiologica Scandinavica》2023,67(8):994-1017
The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40 , 59–74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51 , 789–808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception. 相似文献
52.
Stefaniuk Catherine M. Schlegelmilch June Meyerson Howard J. Harding Clifford V. Maitta Robert W. 《Journal of thrombosis and thrombolysis》2022,53(4):950-953
Journal of Thrombosis and Thrombolysis - Over the last few years data from our group have indicated that α-synuclein is important in development of immune cells as well as potentially... 相似文献
53.
Michael J. Rigby 《Child: care, health and development》2022,48(1):170-174
While children in general are usually seen as a societal priority, many children are disadvantaged by marginalization, with adverse effects on health and development. Following feasibility studies, the European Commission has now adopted a formal Child Guarantee of service access. This paper links the Feasibility Studies to other reports on the need to address marginalized and institutionalized children. The problems in identifying and quantifying such children are outlined, as are the challenges of planning for these groups of children and the difficulty of finding universal definitions and data. This European Union initiative is timely, given that around a quarter of European children are marginalized, while the effects of Covid-19 will add to this marginalization. 相似文献
54.
Bartz Hans-Jürgen 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(3):293-301
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Das klinische Risikomanagement (kRM) unterstützt Mitarbeitende im Gesundheitswesen dabei, Risiken bei der... 相似文献
55.
Troppmair Teresa Egger J. Krösbacher A. Zanvettor A. Schinnerl A. Neumayr A. Baubin M. 《Der Anaesthesist》2022,71(4):272-280
Die Anaesthesiologie - Die Qualität eines Rettungssystems zeichnet sich auch durch den effizienten Einsatz seiner personellen und Fahrzeugressourcen aus. So können im berechtigten Fall... 相似文献
56.
57.
58.
Patrick Demkowicz BS Renelle Pointdujour-Lim MD Sofia Miguez BA Yesung Lee BS Bailey S. C. L. Jones BS Christopher A. Barker MD Marcus Bosenberg MD PhD David H. Abramson MD Alexander N. Shoushtari MD Harriet Kluger MD Jasmine H. Francis MD Mario Sznol MD Mathieu F. Bakhoum MD PhD 《Cancer》2023,129(20):3275-3286
59.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
60.
Eileen M. Dryden PhD Meaghan A. Kennedy MD MPH Jennifer Conti MPH Jacqueline H. Boudreau MPH Chitra P. Anwar MA Kathryn Nearing PhD MA Camilla B. Pimentel PhD MPH William W. Hung MD MPH Lauren R. Moo MD 《Health services research》2023,58(Z1):26-35